Tabula Rasa price target lowered to $4 from $6 at Piper Sandler

Piper Sandler analyst Jessica Tassan lowered the firm’s price target on Tabula Rasa HealthCare to $4 from $6 and keeps a Neutral rating on the shares. The company raised its fiscal 2022 revenue guidance on a Q3 sales beat but its operating losses widened considerably, Tassan tells investors in a research note. The analyst says questions about revenue mix and margin trends keep her on the sidelines.